<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62905</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Topical tacrolimus is an immunosuppressant that acts through the inhibition of calcineurin and thus of the T cells. This causes a decrease in the production of interleukins, the granulocyte colony stimulating factor, alpha interferon and tumor necrosis factor. Although the use of topical tacrolimus is only indicated for the treatment of moderate or severe atopic dermatitis, its immunosuppressant effect and fewer side effects regarding topical corticosteroids have lead to the increase of its use in other types of inflammatory skin diseases. The purpose of this article is to review the use of tacrolimus in this group of diseases other than atopic dermatitis, this use not being authorized within the data sheet of the drug (AU)</dc:description>
<dc:creator>García-Navarro, X</dc:creator>
<dc:creator>Corella, F</dc:creator>
<dc:creator>Alomar, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tacrolimus tópico es un inmunosupresor que actúa mediante la inhibición de la calcineurina y, por tanto, de las células T, lo cual produce una disminución en la producción de interleucinas, del factor estimulador de colonias granulocíticas, del interferón alfa y del factor de necrosis tumoral. A pesar de que el uso del tacrolimus tópico sólo está indicado para el tratamiento de la dermatitis atópica moderada o severa, su efecto inmunosupresor y su menor número de efectos secundarios respecto a los corticoides tópicos, ha provocado el aumento de su utilización en otro tipo de enfermedades inflamatorias dermatológicas. La finalidad de este artículo es revisar el uso del tacrolimus en este grupo de enfermedades diferentes a la dermatitis atópica y cuyo uso no está autorizado en la ficha técnica del fármaco (AU)</dc:description>
<dc:source>Actas Dermosifiliogr;99(supl.2): 26-35, ene. 2008. ilus</dc:source>
<dc:identifier>ibc-62905</dc:identifier>
<dc:subject>^d30584^s22057</dc:subject>
<dc:subject>^d30103^s22073</dc:subject>
<dc:subject>^d19232^s22057</dc:subject>
<dc:subject>^d19232^s22012</dc:subject>
<dc:subject>^d23473^s22021</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d15222^s22057</dc:subject>
<dc:subject>^d1469^s22057</dc:subject>
<dc:subject>^d33429^s22021</dc:subject>
<dc:subject>^d13255^s22057</dc:subject>
<dc:subject>^d9643^s22080</dc:subject>
<dc:subject>^d30938^s22057</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d308^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30651^s22057</dc:subject>
<dc:subject>^d12002^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d8186^s22057</dc:subject>
<dc:subject>^d3894^s22057</dc:subject>
<dc:subject>^d7344^s22073</dc:subject>
<dc:subject>^d3902^s22057</dc:subject>
<dc:subject>^d9643^s22057</dc:subject>
<dc:subject>^d30677^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200801</dc:date>
</metadata>
</record>
</ibecs-document>
